Market research
4563.TSE AnGes, Inc
TSE JPY Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 620
- Dividend yield
- Not available
- Beta
- 0.57
Profile
Company facts
- Exchange
- TSE
- Currency
- JPY
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- JP3127700007
- Market cap
- 14B
- P/E ratio
- Not available
- Analyst target
- 620
- Dividend yield
- Not available
- Beta
- 0.57
About
About AnGes, Inc
AnGes, Inc. engages in the research and development of gene-based medicines. It develops HGF gene therapy product for the treatment of chronic arterial occlusive disease; NF-KB decoy oligonucleotide for chronic discogenic lumbar back pain; and DNA vaccines for the treatment of hypertension, as well as tie2 agonists for COVID-19/ARDS and drugs for chronic hepatitis B. AnGes, Inc. was formerly known as AnGes MG, Inc. and changed its name to AnGes, Inc. in July 2017. The company was incorporated in 1999 and is headquartered in Ibaraki, Japan.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 4563.TSE discussion.
5 years, 6 months ago
AnGes, Inc is currently in a long term downtrend where the price is trading 33.4% below its 200 day moving average.
From a valuation standpoint, the stock is 4876.8% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 3509.6.
AnGes, Inc's total revenue rose by 318.2% to $12M since the same quarter in the previous year.
Its net income has dropped by 5.6% to $-1B since the same quarter in the previous year.
Finally, its free cash flow fell by 0.0% to $-1B since the same quarter in the previous year.
Based on the above factors, AnGes, Inc gets an overall score of 1/5.